Analysis of Medicine Prices in New Zealand and 16 European Countries

Value in Health

Volumn 18, Issue 4, 2015, Pages 484-492

  Vogler, Sabine ^a   Kilpatrick, Kate ^b   Babar, Zaheer Ud Din ^c  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b WAIKATO HOSPITAL   (New Zealand)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

European Union; medicine prices; New Zealand

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; ARIPIPRAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DARUNAVIR; ESCITALOPRAM; GENERIC DRUG; INDINAVIR; INSULIN LISPRO; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLATE MOFETIL; PIOGLITAZONE; PRASUGREL; SUNITINIB; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COST; DENMARK; DEPRESSION; DIABETES MELLITUS; EUROPEAN; GERMANY; GREECE; HEPATITIS B; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION SERVICE; MARKET; MEDICINE; NEW ZEALAND; POLICY; PORTUGAL; PRIORITY JOURNAL; REIMBURSEMENT; SCHIZOPHRENIA; SPAIN; SWEDEN; SWITZERLAND; THROMBOSIS; UNITED KINGDOM; COMPARATIVE STUDY; DRUG COST; ECONOMIC ASPECT; ECONOMICS; EUROPE; HUMAN; STANDARDS;

DRUG COSTS; DRUGS, GENERIC; ECONOMIC COMPETITION; EUROPE; HUMANS; NEW ZEALAND;

EID: 84931574650     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.01.003     Document Type: Article

References (52)

1. H. Hogerzeil Essential medicines and human rights: what can they learn from each other? Bull WHO 84 2006 371 375
2. H. Hogerzeil The concept of essential medicines: lessons for rich countries BMJ 329 2004 1169
3. World Health Organization WHO Guideline on Country Pharmaceutical Pricing Policies Geneva, Switzerland: WHO 2013
4. Bouvy J, Vogler S. Background paper 8.3. Pricing and reimbursement policies: impacts on innovation. In: World Health Organization, ed., Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper. Geneva, Switzerland: WHO, 2013.
5. European Commission DG Health & Consumers. High Level Pharmaceutical Forum. High Level Pharmaceutical Forum 2005-2008: Conclusions and Recommendations. Brussels, Belgium: European Commission, 2008.
6. European Commission. High Level Group on Innovation and Provision of Medicines - Recommendations for Action. Brussels, Belgium: European Commission, 2002.
7. N. Gregson, K. Sparrowhawk, J. Mauskopf, and J. Paul Pricing medicines: theory and practice, challenges and opportunities Nat Rev 4 2005 121 130
8. Kanavos P, Vandoros S, Irwin R, et al. European Parliament's Committee on Environment, ed. Differences in Costs of Access to Pharmaceutical Products in the EU. Brussels, Belgium: European Parliament, 2011.
9. C. Leopold, A. Mantel-Teeuwisse, and L. Seyfang Impact of external price referencing on medicine prices - a price comparison among 14 European countries South Med Rev 5 2012 34 41
10. P. Danzon Price Comparisons for Pharmaceuticals: A Review of U.S and Cross-National Studies 1999 The Wharton School, University of Pennsylvania Pennsylvania
11. Ball, D. Review Series on Pharmaceutical Pricing Policies and Interventions: Working Paper 3. The regulation of mark-ups in the pharmaceutical supply chain. WHO/HAI 2011. Available from: http://www.haiweb.org/medicineprices/05062011/Mark-ups%20final%20May2011.pdf. [Accessed March 16, 2015].
12. J. Espin, and J. Rovira Analysis of differences and commonalities in pricing and reimbursement systems in Europe 2007 DG Enterprise and Industry of the European Commission Brussels
13. S. Morgan, G. Hanley, M. Mcmahon, and M. Barer Influencing drug prices through formulary-based policies: lesson from New Zealand Healthcare Policy 3 2007 121 140
14. J. Cumming How New Zealand has contained expenditure on drugs BMJ 2010 340
15. Pharmaceutical Management Agency of New Zealand, Wilson K, Bloor R, Jennings D, eds. New Zealand Pharmaceutical Schedule. Wellington, New Zealand: Pharmaceutical Management Agency of New Zealand, 2012.
16. S. Vogler, C. Habl, M. Bogut, and L. Voncina Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union member states Croat Med J 52 2011 183 197
17. S. Vogler, J. Espin, and C. Habl Pharmaceutical Pricing and Reimbursement Information (PPRI) 2008 Austrian Federal Ministry of Health Family and Youth Vienna
18. S. Vogler, C. Habl, and C. Leopold Pharmaceutical Health Information System Hospital Pharma Report 2010 Commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health Vienna
19. S. Vogler, C. Habl, C. Leopold, and I. Rosian-Schikuta Pharmaceutical Pricing and Reimbursement Information (PPRI) Report 2008 Gesundheit Österreich GmbH/Geschäftsbereich ÖBIG Vienna
20. Pharmaceutical Health Information System - Glossary. Vienna: WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, 2011. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/MethodologyTemplate/PHIS%20Glossary-UpdatedApril2011.pdf. [Accessed March 16, 2015].
21. C. Leopold, S. Vogler, and A. Mantel-Teeuwisse Differences in external price referencing in Europe - a descriptive overview Health Policy 104 2012 50 60
22. Organisation for Economic Co-Operation and Development. Value in Pharmaceutical Pricing. Paris, France: Organisation for Economic Co-Operation and Development, 2013.
23. P. Kanavos, W. Schurer, and S. Vogler Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices 2011 Eminet/London School of Economics/Gesundheit Österreich GmbH London/Vienna
24. A. Cameron, M. Ewen, and D. Ross-Degnan Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis Lancet 373 2009 240 249
25. A. Creese Working Paper 5: Sales Taxes on Medicines - Review Series on Pharmaceutical Pricing Policies and Interventions 2011 World Health Organization and Health Action International Geneva
26. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) 2003;Suppl Web Exclusives:W3-521-36.
27. P. Danzon, and L. Chao Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ 19 2000 159 195
28. K. Brekke, T. Holmås, and O. Straume Are Pharmaceuticals Still Inexpensive in Norway? A Comparison of Prescription Drug Prices in Ten European Countries (SNF Report No. 08/10) 2010 Institute for Research in Economics and Business Administration Bergen
29. Organisation for Economic Co-operation and Development. Pharmaceutical Pricing Policies in a Global Market. Paris, France: Organisation for Economic Co-operation and Development, 2008.
30. P. Kanavos, and S. Vandoros Determinants of branded prescription medicine prices in OECD countries Health Econ Pol Law 6 2011 337
31. P. Kanavos, A. Ferrario, S. Vandoros, and G. Anderson Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs Health Aff 32 2013 753 761
32. F. von der Schulenburg, S. Vandoros, and P. Kanavos The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors Health Econ Rev 1 2011 1 8
33. J. Martikainen, I. Kivi, and I. Linnosmaa European prices of newly launched reimbursable pharmaceuticals - a pilot study Health Pol 74 2005 235 246
34. Europe Economics. External Price Referencing. 2013. Available from: http://www.europe-economics.com/publications/external-reference-pricing---final-report.pdf. [Accessed March 16, 2015].
35. S. Simoens International comparison of generic medicine prices Curr Med Res Opin 23 2007 2647 2654
36. S. Vogler How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries Farmeconomia Health Econ Therapeut Pathways 13 2012 29 41
37. P. Dylst, and S. Simoens Does the market share of generic medicines influence the price level? A European analysis Pharmacoeconomics 29 2011 875 882
38. G. Tafuri, A. Creese, and V. Reggi National and international differences in the prices of branded and unbranded medicines J Generic Med 1 2004 120 127
39. S. Morgan, and K. Boothe Prescription drug subsidies in Australia and New Zealand Australian Prescriber 33 2012 2 4
40. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Pharmaceutical policy monitoring exercise with national competent authorities represented in the PPRI (Pharmaceutical Pricing and Reimbursement Information) network Bi-annually, latest update February 2014 (unpublished)
41. Gesundheit Österreich. Pharma Price Information (PPI) service. 2012. Available from: http://www.goeg.at/en/PPI. [Accessed March 17, 2015].
42. General Social Insurance Act § 351c, Federal Law Number 189/1955, latest change by Federal Law Number 434/2013 [in German]. 2014.
43. C. Leopold, A. Mantel-Teeuwisse, and S. Vogler Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries Health Policy 112 2013 209 216
44. P. Danzon, and M. Furukawa International prices and availability of pharmaceuticals in 2005 Health Aff 27 2008 221 233
45. P. Danzon, and J. Kim International price comparisons for pharmaceuticals Pharmacoeconomics 14 1998 115 128
46. C. Leopold, S. Vogler, J. Piessnegger, and A. Bucsics Aktuelle Heilmittelausgaben und arzneipolitische Trends in Europa Soziale Sicherheit 9 2013 414 429
47. W. Hogg, N. Baskerville, and J. Lemelin Cost savings associated with improving appropriate and reducing inappropriate preventive care: cost-consequences analysis. MC Health Serv Res 5 2005 20 35
48. M. Gemmill, S. Thomson, and E. Mossialos What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries Int J Equity Health 7 2008 12
49. A. Kentikelenis, M. Karanikolos, and I. Papanicolas Health effects of financial crisis: omens of a Greek tragedy Lancet 378 2011 1457 1458
50. Z. Babar Increasing prescription charge threatens access to medicine The Dominion Post July 2012 19
51. Radio New Zealand. PM says low income earners will benefit from health improvements. Available from: http://www.radionz.co.nz/news/national/105851/pm-says-low-income-earners-will-benefit-from-health-improvements. [Accessed May 5, 2014].
52. S. Vogler, N. Zimmermann, and C. Habl Discounts and rebates granted to public payers for medicines in European countries South Med Rev 5 2012 38 46